Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
  • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
  • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
  • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/65—Tetracyclines
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P33/00—Antiparasitic agents

Definitions

• the present invention relates to the use of antibiotics as veterinary medicaments for the treatment or prophylaxis of diseases and infections of animals, specifically pigs and poultry.
• Pigs and poultry especially those which are intensively reared or reared in large-scale operations, have a tendency to suffer from or risk catching a variety of diseases and infections, for example Mycoplasma diseases in pigs and poultry, Lawsonia infections and swine dysentery in pigs and necrotic enteritis in poultry.
• Medicaments have been proposed or used for the treatment of individual diseases or infections of these types. Such medicaments are either not in general thought to be highly effective in a wide range of diseases or infections or not thought to be effective at low dosage levels.
• tiamulin which is used to treat swine dysentery, is not effective in Lawsonia and not very effective against Mycoplasma diseases and erythromycin, which is used against Mycoplasma has no reported effect against swine dysentery or Lawsoni .
• the present invention therefore provides for the use of aivlosin, as such or as a pharmacologically acceptable
• non-toxic derivative such as an acid addition salt
• a veterinary medicament for the treatment or prophylaxis of Lawsonia infections or swine dysentery in pigs or necrotic enteritis in poultry, as well as a process for the treatment or control of Lawsonia infections or swine dysentery in pigs, or necrotic enteritis in poultry comprising administering to pigs or poultry as the case may be an effective amount of aivlosin or a pharmacologically effective derivative thereof.
• aivlosin as such or as a pharmacologically acceptable derivative, in the preparation of a veterinary medicament for the treatment or control of
• Mycoplasma diseases in pigs and poultry the medicament being added to food at a level of less than 200 ppm
• the invention also includes a veterinary medicament comprising as active ingredients in admixture aivlosin and a tetracycline, especially chlortetracycline or oxytetracycline .
• It also includes a table coated composition for addition to animal feed (e.g. for pigs or poultry) comprising aivlosin in particulate form coated with polyvinyl pyrrolidone .
• R x is acetyl and R 2 is isovaleryl .
• espinomyceticus ATCC 21574 , Streptomyces mycarofaciens (ATCC 21454) and Streptomyces hygroscopicus (ATCC 21582) , in the presence of the appropriate acyl donor, especially acetyl CoA, isovaleryl CoA, acetic acid, isovaleric acid, potassium, sodium or ammonium salts of those acids, methanol and ethanol esters of these acids, amides of these acids and ct- oxovaleric acid.
• acyl donor especially acetyl CoA, isovaleryl CoA, acetic acid, isovaleric acid, potassium, sodium or ammonium salts of those acids, methanol and ethanol esters of these acids, amides of these acids and ct- oxovaleric acid.
• tylosin derivatives can be administered to humans or animals and refers to their activity against a number of gram-positive bacteria, including some drug-resistant bacteria, but it does not specifically refer to the use of the derivatives in the treatment or control of specific diseases or infections of animals, although it does say that they can be employed on humans, livestock, household pets, laboratory animals and poultry and in the enteral, parenteral or topical control of infectious diseases in a similar manner as for known macrolide antibiotic drugs.
• Aivlosin is available in free form as a white crystalline powder having a melting point of 180° -184 °C, soluble in lower alcohols such as ethanol, ketones such as acetone, ethers such as diethyl ether, esters such as ethyl acetate and aromatic hydrocarbons such as toluene, although it is barely soluble in n-hexane and petroleum ether. It is very soluble in aqueous solutions of pH around and below 7 but less soluble in aqueous solutions of higher pH. Because it is a basic compound it forms acid addition salts, and the use of such salts which are pharmacologically acceptable is also included within the present invention.
• Acids to form acceptable acid addition salts include inorganic acids such as hydrochloric, sulphuric or phosphoric acid and organic acids such as tartaric, acetic, propionic, citric and succinic acids.
• Specific examples of acceptable derivatives are aivlosin hydrochloride (melting point 129-133 °C) and aivlosin tartrate (melting point 119-122°C) .
• Such derivatives are frequently more water-soluble than aivlosin itself and their use may therefore have formulation advantages .
• Aivlosin and appropriate derivatives can be formulated according to the present invention into veterinary medicaments in known ways, for example to provide compositions for oral, enteral or parenteral administration, by admixing with appropriate solid or liquid carriers and excipients for the adminstration route desired.
• Conventional ingredients can be used as carriers and excipients, for example water and salt solutions for liquid formulations and silicaceous materials-silica and silicates (such as hydrated magnesium silicate)-, cereal products (such as soybean meal and wheat flour) and other pharmacologically acceptable solids for solid formulations for oral administration.
• the formulations can also contain further auxiliaries and additives such as minerals, lubricants, preservatives, stabilisers, wetting agents, emulsifiers, buffers and colouring or flavouring materials in a conventional manner.
• auxiliaries and additives such as minerals, lubricants, preservatives, stabilisers, wetting agents, emulsifiers, buffers and colouring or flavouring materials in a conventional manner.
• the aivlosin or derivative in the prophylaxis or control of the diseases mentioned it is particularly convenient to include the aivlosin or derivative as an additive to animal feed or drinking water for the pigs or poultry, but in the treatment of the diseases it can be included in an injectable solution, or a tablet, capsule or syrup, if desired.
• Aivlosin (as such or in the form of an appropriate derivative, for example an acid addition salt such as the tartrate) may be formulated into premixes in various potencies from 1 to 10% by weight.
• a particularly suitable composition for producing such premixes comprises aivlosin salt, filler such as soybean powder and additives such as hydroxypropyl cellulose and has a potency of 180 to 220 mg/g.
• a coated aivlosin (as such or in the form of an appropriate derivative, for example an acid addition salt such as the tartrate) in particulate form coated with polyvinylpyrrolidone .
• Suitable proportions by weight are in the range active ingredient: polyvinyl pyrrolidone 50:1 to 1:1.
• Inert fillers and other ingredients may be present in such compositions, the overall polyvinylpyrrolidone concentration being preferably 0.1 to 10% by weight.
• the veterinary medicament formulations can also contain further active ingredients useful in the treatment of infections .and diseases of pigs and poultry, such as further antibiotics, in particular tetracycline antibiotics, for that purpose.
• further antibiotics in particular tetracycline antibiotics
• veterinary medicament formulations for use either as feed additives or as directly administered preparations may contain any convenient proportion of aivlosin for example from 1% or less to 90% or more, by weight.
• Liquid formulations typically contain 50 to 90% by weight, whereas solid formulations typically contain 1 to 25% by weight.
• Lawsonia infections in pigs they may for example be administered in feed at a rate of 40 to 120 ppm by weight (40-120 g per 1,000 kg of feed) for a period of time long enough to control or treat the disease successfully, for example 7 to 14 days.
• figures of 40 to 100 or 50 to 80 ppm may be used.
• a rate of 50 ppm for 10 days is usually effective in controlling the disease and a rate of 100 ppm for 10 days, is usually very successful in treating it.
• comparable rates and periods may be used; administration in feed at a rate of 50 ppm for 10 days is likely to be effective in preventing an outbreak. Similar or lower rates and times are also expected to be effective when aivlosin or a derivative is used in the treatment or prophylaxis of necrotic enteritis .
• aivlosin formulation can be injected directly into eggs. This also makes day-old chicks negative to pleuro-pneumonia- like organisms (PPLO) .
• PPLO pleuro-pneumonia- like organisms
• the rates of adminstration and periods for which administration is made to treat or control Mycoplasma in poultry and pigs are surprisingly low.
• the original Japanese marketing registration referred to levels of 200 to 400 ppm by weight in feed whereas less than 200 ppm is used in the present invention, preferably 40 - 150 ppm or less for example the ranges mentioned above.
• the adminstration levels based on body weight may be in the range 1 to 8 , preferably
• the amounts of each ingredient may be reduced substantially, for example to one half to one third, of the amount of the same ingredient used alone .
• the mixtures may contain aivlosin and the tetracycline in a wide range of weight ratios, for example 10 parts or less of tetracycline per part of aivlosin by weight, especially 10:1 to 5:1 or 8:1 to 6:1 by weight .
• aivlosin API active pharmaceutical ingredient
• aivlosin 20% 25 parts is mixed with 50 parts of hydrated magnesium silicate (an inert silica) , 24 parts of wheat feed flour and 1 part of liquid paraffin EP as a powder blend to give a solid additive for feedstuff containing 50 kg aivlosin activity per 1000 kg.
• This formulation can be used in pig and poultry feed as in Example 1.
• Example 2 5 parts of aivlosin 20% as used in Example 2 is mixed with 40 parts of hydrated magnesium silicate, 54 parts of wheat feed flour and 1 part of liquid paraffin EP as a powder blend to give a solid additive for feedstuff containing 10 kg aivlosin activity per 1000 kg.
• This formulation can be used in pig and poultry feed as in Example 1.
• Aivlosin is dissolved in water to provide an aqueous solution containing 80-90% aivlosin activity for use in drinking water for pigs or poultry.
• This formulation can be added to drinking water to provide aivlosin concentrations in drinking water in the range 25 to 100 g per 200 litres of drinking water.
• Aivlosin API containing more than 80% w/w aivlosin tartrate was mixed into an 850 kg batch comprising
• Lawsonia infections in pigs are caused by the pathogen Lawsonia intracellularis , which was isolated only some six years ago 5 and is a bacteria residing in the cells of the intestinal wall of the lower small intestine of pigs.
• few antimicrobials have been recognised as effective in preventing and treating the disease, which is widespread throughout the world in its incidence and is of considerable 0 economic importance in pig rearing and breeding.
• Extensive trial work by us both in vitro and in vivo on pigs have shown that aivlosin is very effective in treating the disease and preventing it from spreading further in an infected environment.
• Table 1 shows clinical results of an aivlosin porcine proliferative enteropachy efficacy study carried out by us .
• Aivlosin at an inclusion rate of 50 grams per tonne (1000kg) of feed (50 ppm) , provided for 10 days was effective in controlling the disease, while at 100 ppm for 10 days the outbreak was very successfully treated.
• Swine Dysentery is caused by Brachyspira hyodysenteriae , a bacteria which resides in the lumen of the large intestine of pigs, where it hides in the crypts and feeds on the mucosa. It was formerly treated with nitroimidazoles but these are now banned from use in animals destined for human consumption. Chemicals from the pleuromutilin group, especially tiamulin, are available for treatment of the disease, and tylosin has been suggested for use in the past, although use has decreased dramatically in recent years due to development of tylosin resistance by the pathogen . Aivlosin has been tested in vitro and in vivo by us for its effectiveness against the bacteria as compared with
• aivlosin at 50 ppm performed better than or equal to both tiamulin (in results) and tylosin (in duration) .
• Necrotic enteritis is a disease caused by toxins produced by the bacteria Clostridium perf increns, which can lead to widespread destruction of the gut lining with consequent increases in mortality and low growth rates .
• macrolide antibiotics to treat or control necrotic enteritis, nor is there any expectation that such antibiotics would be useful.
• AIVLOSIN used as an Injection directly into eggs in order to prevent Mycoplasma disease in young chickens . Also to make day old chicks PPLO (Pleuro-pneumonia-like organisms) Negative.
• the absorption of Aivlosin after oral intake is 150- 200% better compared to tylosin, and penetration to target site is better. MIC compared to tylosin is improved.
• the AIVLOSIN injection was prepared by adding 40 g AIVLOSIN Activity using water soluble AIVLOSIN to 1 litre of sterile saline. The following trial was carried out for the purpose of studying the effect of AIVLOSIN injected in ovo, against Mycoplasma for chicken and turkeys .

Landscapes

• Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• General Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Organic Chemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Epidemiology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Oncology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Communicable Diseases (AREA)
• Tropical Medicine & Parasitology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Fodder In General (AREA)
• Saccharide Compounds (AREA)
• Medicinal Preparation (AREA)
• Feed For Specific Animals (AREA)

Priority Applications (15)

Applications Claiming Priority (2)

Related Child Applications (1)

Publications (2)

Family

ID=9901546

Family Applications (1)

Country Status (20)

Cited By (5)

Families Citing this family (6)

Family Cites Families (9)

• 2000
  • 2000-10-18 GB GBGB0025556.2A patent/GB0025556D0/en not_active Ceased
• 2001
  • 2001-10-15 PL PL362085A patent/PL221310B1/pl unknown
  • 2001-10-15 PT PT01976452T patent/PT1326599E/pt unknown
  • 2001-10-15 CN CNA018173683A patent/CN1469742A/zh active Pending
  • 2001-10-15 CN CNA2005100910953A patent/CN1803141A/zh active Pending
  • 2001-10-15 DK DK01976452T patent/DK1326599T3/da active
  • 2001-10-15 BR BRPI0114703A patent/BRPI0114703B1/pt active IP Right Grant
  • 2001-10-15 RU RU2003114412/15A patent/RU2310446C2/ru active
  • 2001-10-15 CN CNA2005100910949A patent/CN1803140A/zh active Pending
  • 2001-10-15 CN CNA2005100893680A patent/CN1771980A/zh active Pending
  • 2001-10-15 KR KR1020037004964A patent/KR100866021B1/ko not_active Expired - Lifetime
  • 2001-10-15 US US10/398,086 patent/US20040082524A1/en not_active Abandoned
  • 2001-10-15 RU RU2007105450/15A patent/RU2454230C2/ru active
  • 2001-10-15 CN CN2005100910864A patent/CN1853644B/zh not_active Expired - Lifetime
  • 2001-10-15 AU AU2001295722A patent/AU2001295722A1/en not_active Abandoned
  • 2001-10-15 ES ES01976452T patent/ES2278788T3/es not_active Expired - Lifetime
  • 2001-10-15 CN CNB2005100910968A patent/CN100471501C/zh not_active Expired - Lifetime
  • 2001-10-15 BR BR122013012292A patent/BR122013012292B1/pt active IP Right Grant
  • 2001-10-15 BR BR122013012293A patent/BR122013012293B1/pt active IP Right Grant
  • 2001-10-15 CA CA002425319A patent/CA2425319C/en not_active Expired - Lifetime
  • 2001-10-15 JP JP2002535483A patent/JP4335524B2/ja not_active Expired - Lifetime
  • 2001-10-15 WO PCT/GB2001/004575 patent/WO2002032233A2/en not_active Ceased
  • 2001-10-15 EP EP01976452A patent/EP1326599B1/en not_active Expired - Lifetime
  • 2001-10-15 AT AT01976452T patent/ATE347888T1/de active
  • 2001-10-15 DE DE60125212T patent/DE60125212T2/de not_active Expired - Lifetime
  • 2001-10-15 BR BR122013012291A patent/BR122013012291B1/pt active IP Right Grant
  • 2001-10-15 MX MXPA03003309A patent/MXPA03003309A/es active IP Right Grant
  • 2001-10-17 AR ARP010104881A patent/AR031002A1/es not_active Application Discontinuation
• 2006
  • 2006-06-30 US US11/479,721 patent/US20060247184A1/en not_active Abandoned
• 2007
  • 2007-03-12 CY CY20071100335T patent/CY1107480T1/el unknown
• 2008
  • 2008-07-18 KR KR1020087017633A patent/KR100919725B1/ko not_active Expired - Fee Related
  • 2008-07-28 JP JP2008194051A patent/JP5001234B2/ja not_active Expired - Lifetime
• 2014
  • 2014-11-03 AR ARP140104085A patent/AR098251A2/es not_active Application Discontinuation

Also Published As

Similar Documents

Legal Events